SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

Capstone Energy+, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

14067D607

(CUSIP Number)

Colin J. Daniels, Esq.
Monarch Alternative Capital LP, 535 Madison Avenue
New York, NY, 10022
(212) 554-1700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/23/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP Number(s):	14067D607

1	**Name of reporting person** Monarch Alternative Capital LP
2	**Check the appropriate box if a member of a Group (See Instructions)** ☐ (a) ☑ (b)
3	**SEC use only**

4	**Source of funds (See Instructions)** OO
5	**Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)** ☐
6	**Citizenship or place of organization** DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	

7	**Sole Voting Power** 0.00
8	**Shared Voting Power** 19,333,334.00
9	**Sole Dispositive Power** 0.00
10	**Shared Dispositive Power** 19,333,334.00

11	**Aggregate amount beneficially owned by each reporting person** 19,333,334.00
12	**Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)** ☐
13	**Percent of class represented by amount in Row (11)** 39.8 %
14	**Type of Reporting Person (See Instructions)** IA, PN

Comment for Type of Reporting Person:
IA, PN

SCHEDULE 13D

CUSIP Number(s):	14067D607

1	**Name of reporting person** MDRA GP LP
2	**Check the appropriate box if a member of a Group (See Instructions)** ☐ (a) ☑ (b)
3	**SEC use only**
4	**Source of funds (See Instructions)** OO
5	**Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)** ☐

6	**Citizenship or place of organization** DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 — **Sole Voting Power** 0.00
	8 — **Shared Voting Power** 19,333,334.00
	9 — **Sole Dispositive Power** 0.00
	10 — **Shared Dispositive Power** 19,333,334.00
11	**Aggregate amount beneficially owned by each reporting person** 19,333,334.00
12	**Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)** ☐
13	**Percent of class represented by amount in Row (11)** 39.8 %
14	**Type of Reporting Person (See Instructions)** HC, PN

Comment for Type of Reporting Person:
PN, HC

SCHEDULE 13D

CUSIP Number(s):	14067D607

1	**Name of reporting person** Monarch GP LLC
2	**Check the appropriate box if a member of a Group (See Instructions)** ☐ (a) ☑ (b)
3	**SEC use only**
4	**Source of funds (See Instructions)** OO
5	**Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)** ☐
6	**Citizenship or place of organization** DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	**Sole Voting Power** 0.00
	8	**Shared Voting Power** 19,333,334.00
	9	**Sole Dispositive Power** 0.00
	10	**Shared Dispositive Power** 19,333,334.00
11	**Aggregate amount beneficially owned by each reporting person** 19,333,334.00	
12	**Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)** ☐	
13	**Percent of class represented by amount in Row (11)** 39.8 %	
14	**Type of Reporting Person (See Instructions)** HC, OO	

Comment for Type of Reporting Person:
OO, HC

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock, par value $0.001 per share

(b) Name of Issuer:

Capstone Energy+, Inc.

(c) Address of Issuer's Principal Executive Offices:

16640 STAGG STREET, VAN NUYS, CALIFORNIA , 91406.

Item 1 Comment:
The following constitutes Amendment No. 2 to the Schedule 13D (the "Original 13D") initially filed by the undersigned on April 3, 2026, as amended by Amendment No. 1 thereto filed on June 29, 2026, as specifically set forth herein (this "Amendment"). Except as otherwise set forth herein, the Original 13D is unchanged.

Item 4. Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended to add the following:

As previously disclosed, the Monarch Funds have certain rights to appoint two individuals as directors of the Issuer. On October 23, 2026, the Monarch Funds designated Brandon Schwertner for appointment to the Board as a Series A Director pursuant to the Certificate of Designation. Mr. Schwertner's appointment was approved by the Board on October 26, 2026.

In addition, the Issuer has outstanding secured notes due December 7, 2026 (the "Notes"), which Notes were issued under the Note Purchase Agreement, dated December 7, 2023, by and among the Issuer's operating subsidiary and the purchasers party thereto. The Reporting Persons intend to discuss with the Issuer various options with respect to the forthcoming maturity of the Notes, which discussions may include proposals that may address, among other things, the terms, structure and timing of potential refinancing of the Notes and the potential participation of the Reporting Persons or their affiliates in any refinancing. Any such proposals, and any resulting transaction, may relate to or result in one or more of the matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

As of the date of this Amendment, the Reporting Persons have not reached any agreements or made any offers to the Issuer in respect of the Notes. There can be no assurance that any offer will be made, nor that the Issuer or the Reporting Persons will agree to any refinancing or related transaction. The nature of any terms or conditions that may be proposed or agreed with respect to any refinancing or related transaction are uncertain and subject to further discussion and negotiation, and there is no assurance that any refinancing or related transaction will be agreed to or ultimately consummated. The Reporting Persons reserve the right to take or not take any actions, including modifying or withdrawing any potential proposal, and discontinuing any discussions with the Issuer at any time. Any definitive agreement would be subject to, among other things, negotiation and execution of definitive documentation, approval by the Board and the Reporting Persons' investment committee processes, and the receipt of any required consents.

Item 5. Interest in Securities of the Issuer

(a) The information contained on the cover pages of this Schedule 13D is incorporated into this Item 5 by reference.

The number of shares of Common Stock beneficially owned by the Reporting Persons remains unchanged from the initial Schedule 13D filed by the Reporting Persons and consists of 3,333,334 shares of Common Stock and 16,000,000 shares of Common Stock issuable upon conversion of the Series A Preferred Stock at the initial Conversion Price.

The percentages used in this Amendment are calculated based upon 32,611,589 shares of Common Stock outstanding as of August 7, 2026, as reported in the Q1 10-Q, plus 16,000,000 shares of Common Stock issuable upon conversion of the Series A Preferred Stock beneficially owned by the Reporting Persons at the initial Conversion Price.

(b) The information contained on the cover pages of this Schedule 13D is incorporated into this Item 5 by reference.

The number of shares of Common Stock beneficially owned by the Reporting Persons remains unchanged from the initial Schedule 13D filed by the Reporting Persons and consists of 3,333,334 shares of Common Stock and 16,000,000 shares of Common Stock issuable upon conversion of the Series A Preferred Stock at the initial Conversion Price.

The percentages used in this Amendment are calculated based upon 32,611,589 shares of Common Stock outstanding as of August 7, 2026, as reported in the Q1 10-Q, plus 16,000,000 shares of Common Stock issuable upon conversion of the Series A Preferred Stock beneficially owned by the Reporting Persons at the initial Conversion Price.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Monarch Alternative Capital LP

Signature: **/s/ Colin J. Daniels**
Name/Title: **Colin J. Daniels/Managing Director, General Counsel**
Date: **10/26/2026**

MDRA GP LP

Signature: **Monarch GP LLC**
Name/Title: **General partner**
Date: **10/26/2026**

Signature: **/s/ Colin J. Daniels**
Name/Title: **Colin J. Daniels/Authorized Person**
Date: **10/26/2026**

Monarch GP LLC

Signature: **/s/ Colin J. Daniels**
Name/Title: **Colin J. Daniels/Authorized Person**
Date: **10/26/2026**